Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDRYZK)

Drug Name
Anti-CD19 CAR-T cells Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute lymphocytic leukaemia 2B33.3 Phase 1/2 [1]
B-cell prolymphocytic leukaemia 2A82.1 Phase 1/2 [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [1]
Diffuse large B-cell lymphoma 2A81 Phase 1/2 [1]
Follicular lymphoma 2A80 Phase 1/2 [1]
Mantle cell lymphoma 2A85.5 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMDRYZK

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
B-lymphocyte surface antigen B4 (CD19) DTT CD19 5.758 6.211 6.083 5.396
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute lymphocytic leukaemia
ICD Disease Classification 2B33.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma